Clinical trial

Comparison of Sequential to Initial Combination Therapy in PAH

NCT06968962

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-05-14

PhaseNA

Study timeline

Study start (actual)2025-05-14Date precision: day

Registry last updated2025-07-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Pulmonary Arterial Hypertension (PAH)unresolved

Interventions

TadalafilDRUG · verified · RxNorm: tadalafil

AmbrisentanDRUG · verified · RxNorm: ambrisentan

Ambrisentan mimicDRUG

Tadalafil mimicDRUG

Sponsors & collaborators

Second Affiliated Hospital, Zhejiang University, School of Medicinelead sponsor

Huzhou Central Hospitalcollaborator

Ningbo Medical Center Lihuili Hospitalcollaborator

First Affiliated Hospital of Ningbo Universitycollaborator

Ningbo No.2 Hospitalcollaborator

Affiliated Hospital of Jiaxing Universitycollaborator

The Second Affiliated Hospital of Jiaxing Universitycollaborator

First Affiliated Hospital of Wenzhou Medical Universitycollaborator

Shanghai Pulmonary Hospital, Shanghai, Chinacollaborator

Taizhou Hospitalcollaborator

Guangdong Provincial People's Hospitalcollaborator

Mapped research locations

HangzhouZhejiang, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06968962 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.